Cargando…

Antitumor Effect of Cabozantinib in Bone Metastatic Models of Renal Cell Carcinoma

SIMPLE SUMMARY: Bone metastasis is a common and devastating feature of advanced renal cancer. Skeletal metastases are very destructive in patients with renal cell carcinoma (RCC), compromising the bone integrity and leading to fractures, pain, nerve compressions and hypercalcemia, with a negative im...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iuliani, Michele, Simonetti, Sonia, Pantano, Francesco, Ribelli, Giulia, Di Martino, Alberto, Denaro, Vincenzo, Vincenzi, Bruno, Russo, Antonio, Tonini, Giuseppe, Santini, Daniele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389553/ https://www.ncbi.nlm.nih.gov/pubmed/34440012 http://dx.doi.org/10.3390/biology10080781

Ejemplares similares

Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions
por: Fioramonti, Marco, et al.
Publicado: (2017)

Current and Emerging Biomarkers Predicting Bone Metastasis Development
por: Iuliani, Michele, et al.
Publicado: (2020)

Osteoblasts Promote Prostate Cancer Cell Proliferation Through Androgen Receptor Independent Mechanisms
por: Ribelli, Giulia, et al.
Publicado: (2021)

Osteoblast Secretome Modulated by Abiraterone Treatment Affects Castration Resistant Prostate Cancer Cell Proliferation
por: Iuliani, Michele, et al.
Publicado: (2022)

Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment
por: Iuliani, Michele, et al.
Publicado: (2022)

Dynamic changes of Receptor activator of nuclear factor-κB expression in Circulating Tumor Cells during Denosumab predict treatment effectiveness in Metastatic Breast Cancer
por: Pantano, Francesco, et al.
Publicado: (2020)

Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-Β ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma
por: Simonetti, Sonia, et al.
Publicado: (2022)

Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment
por: Fioramonti, M., et al.
Publicado: (2018)

Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples
por: Russano, Marco, et al.
Publicado: (2020)

Correction to: Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples
por: Russano, Marco, et al.
Publicado: (2020)

Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw
por: Vincenzi, Bruno, et al.
Publicado: (2012)

Cabozantinib and apixaban: an hitherto unreported interaction
por: Santini, Daniele, et al.
Publicado: (2019)

Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence
por: Santini, Daniele, et al.
Publicado: (2015)

MicroRNAs and Bone Metastasis: A New Challenge
por: Croset, Martine, et al.
Publicado: (2014)

Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment
por: Iuliani, Michele, et al.
Publicado: (2015)

Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions
por: Pantano, Francesco, et al.
Publicado: (2021)

Large-Scale Profiling of Extracellular Vesicles Identified miR-625-5p as a Novel Biomarker of Immunotherapy Response in Advanced Non-Small-Cell Lung Cancer Patients
por: Pantano, Francesco, et al.
Publicado: (2022)

Classification of M1/M2-polarized human macrophages by label-free hyperspectral reflectance confocal microscopy and multivariate analysis
por: Bertani, Francesca R., et al.
Publicado: (2017)

Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis
por: Pantano, Francesco, et al.
Publicado: (2022)

Targeting bone metastases starting from the preneoplastic niche: home sweet home
por: Santini, Daniele, et al.
Publicado: (2011)

First-line targeted therapies in the treatment of metastatic colorectal cancer – role of cetuximab
por: Tonini, Giuseppe, et al.
Publicado: (2009)

Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer
por: Tonini, Giuseppe, et al.
Publicado: (2013)

Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer
por: Santini, Daniele, et al.
Publicado: (2006)

Deregulation of dicer and mir-155 expression in liposarcoma
por: Vincenzi, Bruno, et al.
Publicado: (2015)

Facing SARS-CoV-2 outbreak in immunotherapy era
por: Citarella, Fabrizio, et al.
Publicado: (2020)

Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma
por: Vincenzi, Bruno, et al.
Publicado: (2017)

Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma
por: Colomba, Emeline, et al.
Publicado: (2022)

Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma
por: Vecchio, Sharon J. Del, et al.
Publicado: (2018)

Coronavirus Disease 2019 or Lung Cancer: What Should We Treat?
por: Russano, Marco, et al.
Publicado: (2020)

Tumor associated macrophages polarization dictates the efficacy of BCG instillation in non-muscle invasive urothelial bladder cancer
por: Suriano, Francesca, et al.
Publicado: (2013)

Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?
por: Dell’Aquila, Emanuela, et al.
Publicado: (2020)

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential
por: Bersanelli, Melissa, et al.
Publicado: (2017)

Exposure–response analyses of cabozantinib in patients with metastatic renal cell cancer
por: Krens, Stefanie D., et al.
Publicado: (2022)

Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study
por: Vano, Yann‐Alexandre, et al.
Publicado: (2022)

Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas
por: Thouvenin, Jonathan, et al.
Publicado: (2022)

Response to: Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations
por: Citarella, Fabrizio, et al.
Publicado: (2021)

Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors
por: Santoni, Matteo, et al.
Publicado: (2019)

Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma
por: Wiecek, Witold, et al.
Publicado: (2016)

Evidence-based guidelines: Improving AGREEment on consistence evaluation
por: Vincenzi, Bruno, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_st1ebrq32bimumabp0dn4jnk96